Advertisement

Clinical Rheumatology

, Volume 38, Issue 2, pp 591–596 | Cite as

Efficacy of new treatments for dactylitis of psoriatic arthritis: update of literature review

  • Maxime SondagEmail author
  • Frank Verhoeven
  • Xavier Guillot
  • Clément Prati
  • Daniel Wendling
Brief Report

Abstract

Dactylitis is a frequent disabling feature of psoriatic arthritis (PsA). Therapeutic strategy on dactylitis is not really codified. We performed a complementary literature review (since a previous one in 2014) of efficacy of new treatments recently used in PsA on this specific clinical manifestation. Eleven publications were retained (4697 patients). In the randomized double-blind placebo-controlled trials analyzed, authors declared ustekinumab, ixekizumab, adalimumab, and apremilast efficient. Secukinumab, clazakizumab, abatacept, and tofacitinib were promising. Brodalumab was ineffective. Calculations of odds ratios for residual dactylitis were significant for clazakizumab 100 mg and secukinumab in anti-TNF-naïve population. Homogenization of dactylitis assessment and use of this criterion as primary outcome are necessary to have better data on treatment efficacy in the future.

Keywords

Dactylitis Literature review Psoriatic arthritis Treatment 

Notes

Compliance with ethical standards

Disclosures

None.

References

  1. 1.
    Yamamoto T (2015) Optimal management of dactylitis in patients with psoriatic arthritis. Open Access Rheumatol Res Rev 7:55–62.  https://doi.org/10.2147/OARRR.S60821 Google Scholar
  2. 2.
    Baranauskaite A, Raffayová H, Kungurov NV, Kubanova A, Venalis A, Helmle L, Srinivasan S, Nasonov E, Vastesaeger N, RESPOND investigators (2012) Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis 71:541–548.  https://doi.org/10.1136/ard.2011.152223 CrossRefGoogle Scholar
  3. 3.
    Gladman DD, Ziouzina O, Thavaneswaran A, Chandran V (2013) Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. J Rheumatol 40:1357–1359.  https://doi.org/10.3899/jrheum.130163 CrossRefGoogle Scholar
  4. 4.
    Rose S, Toloza S, Bautista-Molano W, Helliwell PS, on behalf of the GRAPPA Dactylitis Study Group, Adebajo A, Carneiro S, Haddad A, Kaeley G, Kafka S, Moverley A, Nadashkevich O, Parkinson A, Queiro R, Schainberg C, Ucar U, Valle-Onate R, Zmierczak HG (2014) Comprehensive treatment of dactylitis in psoriatic arthritis. J Rheumatol 41:2295–2300.  https://doi.org/10.3899/jrheum.140879 CrossRefGoogle Scholar
  5. 5.
    Ramiro S, Smolen JS, Landewé R, van der Heijde D, Dougados M, Emery P, de Wit M, Cutolo M, Oliver S, Gossec L (2016) Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 75:490–498.  https://doi.org/10.1136/annrheumdis-2015-208466 CrossRefGoogle Scholar
  6. 6.
    Kavanaugh A, Husni ME, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC (2017) Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT study. Arthritis Rheumatol Hoboken NJ 69:2151–2161.  https://doi.org/10.1002/art.40226 CrossRefGoogle Scholar
  7. 7.
    Kavanaugh A, Puig L, Gottlieb AB, Ritchlin C, You Y, Li S, Song M, Randazzo B, Rahman P, McInnes IB (2016) Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). Ann Rheum Dis 75:1984–1988.  https://doi.org/10.1136/annrheumdis-2015-209068 CrossRefGoogle Scholar
  8. 8.
    Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, Stevens RM, Vessey A, Zhan X, Bird P (2016) Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis 75:1065–1073.  https://doi.org/10.1136/annrheumdis-2015-207963 CrossRefGoogle Scholar
  9. 9.
    Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD, SPIRIT-P1 Study Group (2017) Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis 76:79–87.  https://doi.org/10.1136/annrheumdis-2016-209709 CrossRefGoogle Scholar
  10. 10.
    McInnes IB, Mease PJ, Kirkham B et al (2015) Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl 386:1137–1146.  https://doi.org/10.1016/S0140-6736(15)61134-5 CrossRefGoogle Scholar
  11. 11.
    Kavanaugh A, McInnes IB, Mease PJ et al (2016) Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study. J Rheumatol 43:1713–1717.  https://doi.org/10.3899/jrheum.160275 CrossRefGoogle Scholar
  12. 12.
    Mease PJ, Gottlieb AB, Berman A, Drescher E, Xing J, Wong R, Banerjee S (2016) The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis. Arthritis Rheumatol Hoboken NJ 68:2163–2173.  https://doi.org/10.1002/art.39700 CrossRefGoogle Scholar
  13. 13.
    Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, Kanik KS (2017) Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med 377:1525–1536.  https://doi.org/10.1056/NEJMoa1615977 CrossRefGoogle Scholar
  14. 14.
    Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, Cieślak D, Graham D, Wang C, Menon S, Hendrikx T, Kanik KS (2017) Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 377:1537–1550.  https://doi.org/10.1056/NEJMoa1615975 CrossRefGoogle Scholar
  15. 15.
    Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, Banerjee S, Gladman DD (2017) Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis 76:1550–1558.  https://doi.org/10.1136/annrheumdis-2016-210724 CrossRefGoogle Scholar
  16. 16.
    Mease PJ, Genovese MC, Greenwald MW, Ritchlin CT, Beaulieu AD, Deodhar A, Newmark R, Feng JY, Erondu N, Nirula A (2014) Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 370:2295–2306.  https://doi.org/10.1056/NEJMoa1315231 CrossRefGoogle Scholar
  17. 17.
    Helliwell PS, Firth J, Ibrahim GH, Melsom RD, Shah I, Turner DE (2005) Development of an assessment tool for dactylitis in patients with psoriatic arthritis. J Rheumatol 32:1745–1750Google Scholar
  18. 18.
    Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Lespessailles E, Hall S, Hochfeld M, Hu CC, Hough D, Stevens RM, Schett G (2014) Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 73:1020–1026.  https://doi.org/10.1136/annrheumdis-2013-205056 CrossRefGoogle Scholar
  19. 19.
    Carron P, Varkas G, Cypers H, van Praet L, Elewaut D, van den Bosch F, CRESPA investigator group (2017) Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study. Ann Rheum Dis 76:1389–1395.  https://doi.org/10.1136/annrheumdis-2016-210775 CrossRefGoogle Scholar
  20. 20.
    Mease P, Sieper J, Van den Bosch F et al (2015) Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis. Arthritis Rheumatol Hoboken NJ 67:914–923.  https://doi.org/10.1002/art.39008 CrossRefGoogle Scholar
  21. 21.
    Coates LC, Helliwell PS (2016) Methotrexate efficacy in the tight control in psoriatic arthritis study. J Rheumatol 43:356–361.  https://doi.org/10.3899/jrheum.150614 CrossRefGoogle Scholar
  22. 22.
    Healy PJ, Helliwell PS (2007) Measuring dactylitis in clinical trials: which is the best instrument to use? J Rheumatol 34:1302–1306Google Scholar
  23. 23.
    Feletar M, Hall S, Bird P (2016) Evaluation of magnetic resonance imaging responsiveness in active psoriatic arthritis at multiple timepoints during the first 12 weeks of antitumor necrosis factor therapy. J Rheumatol 43:75–80.  https://doi.org/10.3899/jrheum.150347 CrossRefGoogle Scholar
  24. 24.
    Vieira-Sousa E, Alves P (2015) Dactylitis: more than just arthritis. Acta Reumatol Port 40:210–212Google Scholar
  25. 25.
    Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, Bautista-Molano W, Boehncke WH, Campbell W, Cauli A, Espinoza LR, FitzGerald O, Gladman DD, Gottlieb A, Helliwell PS, Husni ME, Love TJ, Lubrano E, McHugh N, Nash P, Ogdie A, Orbai AM, Parkinson A, O'Sullivan D, Rosen CF, Schwartzman S, Siegel EL, Toloza S, Tuong W, Ritchlin CT (2016) Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol Hoboken NJ 68:1060–1071.  https://doi.org/10.1002/art.39573 Google Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  • Maxime Sondag
    • 1
    Email author
  • Frank Verhoeven
    • 1
  • Xavier Guillot
    • 1
  • Clément Prati
    • 1
  • Daniel Wendling
    • 1
  1. 1.Rheumatology DepartmentCHRU Jean MinjozBesançonFrance

Personalised recommendations